Use of Electronic Clinical Data to Track Incidence and Mortality for SARS-CoV-2–Associated Sepsis
Authors' conclusion
In this retrospective cohort study of hospitalized adults, SARS-CoV-2 accounted for approximately 1 in 6 cases of sepsis during the first 33 months of the COVID-19 pandemic. In-hospital mortality rates for SARS-CoV-2-associated sepsis were high but declined over time and ultimately were similar to presumed bacterial sepsis.
Study context
- Population
- Adults hospitalized at 5 Massachusetts hospitals, March 2020–November 2022
- Participants
- 431,017 hospital encounters
- Exposure
- SARS-CoV-2-associated sepsis vs presumed bacterial sepsis
- SARS-CoV-2-associated sepsisn = 6,558
- Presumed bacterial sepsisn = 30,604reference
- Outcome
- Trends in quarterly incidence (proportion of hospitalizations) and in-hospital mortality for SARS-CoV-2-associated and presumed bacterial sepsis
Methodological detailsmulticentre, electronic clinical criteria
- Multicentre
- Electronic clinical criteria
Main finding
As reported in the abstract
Incidence and in-hospital mortality
Adjusted odds ratio per quarter (mortality trend) (95% CI)
SARS-CoV-2-associated sepsis vs Presumed bacterial sepsis
0.88(0.85–0.90)
Presumed bacterial sepsisstable across quarters
1.00(0.99–1.01)
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Validity of EHR-based SARS-CoV-2-associated sepsis criteria vs sepsis-3 (medical record review of 200 SARS-CoV-2-positive hospitalizations) | EHR-based criteria sensitivity 90.6% (95% CI, 80.7%-96.5%) · specificity 91.2% (95% CI, 85.1%-95.4%) |
Original publication
Use of Electronic Clinical Data to Track Incidence and Mortality for SARS-CoV-2–Associated Sepsis. JAMA Netw Open. Published 5 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →